{"id":"NCT01895972","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT","officialTitle":"A Single-Arm, Multicenter, Open-Label Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07-05","primaryCompletion":"2015-04-02","completion":"2015-04-14","firstPosted":"2013-07-11","resultsPosted":"2018-06-06","lastUpdate":"2018-07-26"},"enrollment":130,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Latanoprostene bunod","otherNames":["BOL-303259-X"]}],"arms":[{"label":"Latanoprostene Bunod","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.","primaryOutcome":{"measure":"Change From Baseline in Intraocular Pressure","timeFrame":"Baseline and week 4,8,12,16,20,24,28,32,36,40,44,48,52","effectByArm":[{"arm":"Latanoprostene Bunod","deltaMin":-4.3,"sd":2.746}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["27457469"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":130},"commonTop":["Conjunctival hyperemia","Growth of eyelashes","Eye irritation","Eye pain","Iris hyperpigmentation"]}}